The Commercial Potential Of Big Data In Healthcare

Thursday, January 23, 2014 6:30 PM - 9:30 PM Amphitheatre, Duke-NUS Graduate Medical School 8 College Rd Singapore 169857 (map) [bs-social-share style="button-no-text" colored="0" sites="facebook,twitter,whatsapp,email" title="Share" show_title="0" icon="" heading_color="" heading_style="default" bs-show-desktop="1" bs-show-tablet="1" bs-show-phone="1" bs-text-color-scheme="" custom-css-class="" custom-id="" css=""] The era of Big Data is upon us. Advances in technology allow us not Read more…

Fireside Chat with Philip Yeo: Failure and Innovation

Tuesday, November 5, 2013 6:00 PM - 9:00 PM [bs-social-share style="button-no-text" colored="0" sites="facebook,twitter,whatsapp,email" title="Share" show_title="0" icon="" heading_color="" heading_style="default" bs-show-desktop="1" bs-show-tablet="1" bs-show-phone="1" bs-text-color-scheme="" custom-css-class="" custom-id="" css=""] The Medical Technology sector has been identified as a key growth area for Singapore’s future economy. The growth of our local corporate enterprise is pivotal Read more…

The Future of Biotech In Singapore: Towards A Self-Sustaining System

Singapore’s biomedical sciences (BMS) initiative began with a bang in 2000 with a S$6 billion government commitment over 5 years earmarked to establish new research centres, attract multi-national companies (MNCs), and to build infrastructure such as the Biopolis. Government spending on R&D has now increased to S$16.1 billion for phase 3 of the BMS initiative from 2011 to 2015, with the aim of “capturing opportunities for greater economic and health impact”.